This webinar on May 8th discussed how exploratory surrogate endpoints and companion diagnostics (CDX) are transforming clinical trial design in immuno-oncology, crucial for advancing personalized medicine. By incorporating these innovative approaches, researchers can gain early insights into treatment efficacy, enhancing the likelihood of successful drug approval. Join us to explore how these guidelines and best practices can shape the future of clinical trials and drive progress in immunotherapy. View the webinar for FREE on-demand HERE.